reports
- Research Team ACF
Sana Biotechnology (SANA) Core Investment Case 05022025
Sana Biotechnology (NasdaqGS:SANA) is a well-funded cell and gene therapy innovator. Its therapies address significant unmet needs across oncology, central nervous system (CNS) disorders, and rare genetic diseases. Leveraging IP protected platform technologies, SANA is developing a robust pipeline of allogeneic cell therapies, in vivo gene editing and hypoimmune solutions, that might revolutionize treatment paradigms. SANA has a potentially transformative approach to cell and gene therapy via it...
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcar...
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of...
Sana Biotechnology Announces Positive Clinical Results from Type 1 Dia...
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of ...
Sana Biotechnology Announces Fast Track Designation for SC291 in Relap...
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and...
Sana Biotechnology to Present at December 2024 Investor Conferences
Sana Biotechnology to Present at December 2024 Investor Conferences SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will participate on a panel at Citi’s 2024 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 3, 2024.Sana will present a...
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Bu...
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells, GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025Announced increased focus on type 1 diabetes and...
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-...
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells Modified strategy extends expected cash runway into 2026 with potential for multiple data readouts in 2024 and 2025 SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) ...
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Co...
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website at . ...
Sana Biotechnology to Present at September 2024 Investor Conferences
Sana Biotechnology to Present at September 2024 Investor Conferences SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update. Sana will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024.Sana will present at the 2024 Wells Fargo Healthcare Conference at ...
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, ...
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. “We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipe...
Sana Biotechnology Reports Second Quarter 2024 Financial Results and B...
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in two oncology trials – ARDENT for SC291 in B-cell malignancies and VIVID for SC262 in relapsed/refractory B-cell malignancies; expect to report additional clinical data in 2024 Enrol...
Sana Biotechnology Highlights Publication in Nature Biotechnology of N...
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sa...
Sana Biotechnology Reports First Quarter 2024 Financial Results and Bu...
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to rep...
Sana Biotechnology to Present at May and June 2024 Investor Conference...
Sana Biotechnology to Present at May and June 2024 Investor Conferences SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update. Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m. ET on Monday, May 13, 2024.Sana will present at the BofA Securities 2024 Healthcare Conference at 3:...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
SHBI SHORE BANCSHARES INC.
PNNT PENNANTPARK INVESTMENT
NGL NGL ENERGY PARTNERS LP
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
ATRC ATRICURE INC.
ASYS AMTECH SYSTEMS INC.
HWBK HAWTHORN BANCSHARES
RIGN TRANSOCEAN LTD.
PLBC PLUMAS BANCORP
HCC WARRIOR MET COAL INC.
IOVA IOVANCE BIOTHERAPEUTICS INC
NANX NANOPHASE TECHNOLOGIES CORP.
CSPI CSP INC.
FSK FS KKR CAPITAL CORP
NOVA SUNNOVA ENERGY INTERNATIONAL
MRBK MERIDIAN
PLCE THE CHILDREN'S PLACE RETAIL STORES
LRMR INC.
THRY LARIMAR THERAPEUTICS INC
ABCL THRYV HOLDINGS
LUMN ABCELLERA BIOLOGICS
SANA LUMEN TECHNOLOGIES INC.
ONDS SANA BIOTECHNOLOGY
WES ONDAS HOLDINGS
TRST WESTERN MIDSTREAM PARTNERS LP
STGW TRUSTCO BANK CORP NY
MODD STAGWELL INC
VFC MODULAR MEDICAL INC
GATO VF CORPORATION
CYT SUNSHINE SILVER MINING AND REFINING CORP
ADXS CYTEIR THERAPEUTICS INC
BNL AYALA PHARMACEUTICALS INC
BROADSTONE NET LEASE INC
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial...
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announc...
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Con...
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s website...
- Jonathan Moreland
PNNT PENNANTPARK INVESTMENT
NYCB NEW YORK COMMUNITY BANCORP INC.
NGL NGL ENERGY PARTNERS LP
NBTB NBT BANCORP INC.
MKL MARKEL CORPORATION
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CVBF CVB FINANCIAL CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ADVM ADVERUM BIOTECHNOLOGIES
VIRT VIRTU FINANCIAL INC. CLASS A
HWBK HAWTHORN BANCSHARES
THR THERMON GROUP HOLDINGS
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
CIZN CITIZENS HOLDING CO.
CLSD CLEARSIDE BIOMEDICAL INC
KREF KKR REAL ESTATE FINANCE TRUST
NEE NEXTERA ENERGY
IOVA INC.
NANX IOVANCE BIOTHERAPEUTICS INC
CSPI NANOPHASE TECHNOLOGIES CORP.
PLCE CSP INC.
LRMR THE CHILDREN'S PLACE RETAIL STORES
LUMN INC.
SANA LARIMAR THERAPEUTICS INC
TRST LUMEN TECHNOLOGIES INC.
MODD SANA BIOTECHNOLOGY
BPRN TRUSTCO BANK CORP NY
VFC MODULAR MEDICAL INC
CYT BANK OF PRINCETON
PCSA VF CORPORATION
ADXS CYTEIR THERAPEUTICS INC
PROCESSA PHARMACEUTICALS INC
AYALA PHARMACEUTICALS INC
- Jonathan Moreland
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHBI SHORE BANCSHARES INC.
PNNT PENNANTPARK INVESTMENT
NGL NGL ENERGY PARTNERS LP
MRCY MERCURY SYSTEMS INC.
GPRE GREEN PLAINS INC.
EMKR EMCORE CORP.
BERY BERRY GLOBAL GROUP INC
ASYS AMTECH SYSTEMS INC.
HWBK HAWTHORN BANCSHARES
ADC AGREE REALTY CORPORATION
HI HILLENBRAND INC.
FBK FB FINANCIAL CORPORATION
CSBB C S B BANCORP OHIO
RBB RBB BANCORP
NANX NANOPHASE TECHNOLOGIES CORP.
PLCE THE CHILDREN'S PLACE RETAIL STORES
LRMR INC.
LUMN LARIMAR THERAPEUTICS INC
SANA LUMEN TECHNOLOGIES INC.
ADXS SANA BIOTECHNOLOGY
BPRN ADVAXIS INC
VFC BANK OF PRINCETON
CYT VF CORPORATION
CYTEIR THERAPEUTICS INC
Sana Biotechnology Announces Publication of Preclinical Diabetes Data ...
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration Administration of anti-CD47 antibody after six months demonstrated the principle of graft ablation and a pote...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.